enzon pharmaceuticals inc (ENZN) Key Developments
Enzon Pharmaceuticals Inc. Declares Special Cash Dividend, Payable on December 23, 2013
Dec 5 13
The board of directors of Enzon Pharmaceuticals Inc. declared a special cash dividend of $0.45 per share of the company's common stock, payable on December 23, 2013 to stockholders of record as of December 16, 2013.
Thomas F. Deuel Not to Stand for Re-Election as Director of Enzon Pharmaceuticals, Inc
Oct 22 13
On October 22, 2013, Thomas F. Deuel, who previously informed Enzon Pharmaceuticals Inc. that he will not stand for re-election when his term as a director expires at the company's 2013 annual meeting of stockholders, resigned as a director effective October 22, 2013.
Enzon Pharmaceuticals Inc. Announces Board Changes
Oct 9 13
On October 7, 2013, each of George W. Hebard III and Richard A. Young informed Enzon Pharmaceuticals Inc. that he will not stand for re-election when his term as a director expires at the company's 2013 annual meeting of stockholders to be held on November 20, 2013. On October 7, 2013, the Board of Directors of the Company appointed, effective as of October 7, 2013, Jonathan Christodoro as a director to the Board. Mr. Christodoro has served as a Managing Director of Icahn Capital LP, since July 2012. Mr. Christodoro is responsible for identifying, analyzing and monitoring investment opportunities and portfolio companies for Icahn Capital LP. Following Mr. Hebard's and Dr. Young's decision not to stand for re-election at the 2013 Annual Meeting and the appointment of Mr. Christodoro as a director to the Board, the Board has determined that the following persons will stand for election at the 2013 Annual Meeting: Mr. Christodoro, Odysseas Kostas and Jennifer I. McNealey. On October 8, 2013, each of Robert LeBuhn and Robert C. Salisbury, who previously informed the Company that he will not stand for re-election when his term as a director expires at the 2013 Annual Meeting, resigned as a director effective October 8, 2013.
Enzon Pharmaceuticals Inc. Enters into an Agreement of Sublease with Axcellerate Pharma, LLC
Oct 1 13
On September 26, 2013, Enzon Pharmaceuticals Inc. entered into an Agreement of Sublease with Axcellerate Pharma, LLC pursuant to which the company will sublease to Axcellerate a portion of the company’s premises consisting of approximately 30,000 rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas. The company’s premises located at 20 Kingsbridge Road, Piscataway, New Jersey are currently leased by the company pursuant to an agreement of lease dated as of April 1, 1995, as amended by that certain First Amendment to Lease dated as of November 13, 2001, with BDG Kingsbridge L.L.C., predecessor-in-interest to Kingsbridge 2005, LLC. The Sublease is subject to the company’s receipt of the Prime Landlord’s consent to the Sublease. The term of the Sublease will commence on the date that the company has received the Prime Landlord’s consent to the Sublease and will expire on July 30, 2021, which is one day prior to the expiration of the Prime Lease. The rights of Axcellerate under the Sublease will be subject to the terms of the Prime Lease. The monthly fixed rent payable by Axcellerate under the Sublease will be as follows: in year one, $10,417, in year two, $15,625, in year three, $20,833, in year four, $26,042 and in each of years five through eight, $35,000. The Sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.
Enzon Pharmaceuticals Inc., Annual General Meeting, Nov 20, 2013
Oct 1 13
Enzon Pharmaceuticals Inc., Annual General Meeting, Nov 20, 2013., at 11:00 US Eastern Standard Time. Location: Club 101 on the Main Floor. Agenda: To consider the election of three directors, each for a one-year term expiring at the next annual meeting of stockholders and until such director’s successor is elected and qualified; to consider and ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2013; to consider and approve the compensation of the named executive officers; to consider that Dr. Young will not stand for re-election at the 2013; and to transact such other matters as may properly come before the 2013 Annual Meeting or any adjournment or postponement thereof.